Relationship between the expression of PD-1/PD-L1 and 18 F-FDG uptake in bladder cancer, Eur J Nucl Med Mol Imaging, 2019. ,
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab, Eur J Cancer, vol.2019, pp.234-243 ,
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now, Cancer Treat Rev, vol.54, pp.58-67, 2017. ,
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways, World J Urol, vol.36, issue.11, pp.1727-1740, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02292092
Integrated analysis of 18 F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer, Eur Radiol, 2019. ,
Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose PositronEmission Tomography/Computed Tomography, Cancer Res Treat, vol.47, issue.4, pp.834-877, 2015. ,
Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions, Urol Oncol, 2019. ,
Partial-volume effect in PET tumor imaging, J Nucl Med, vol.48, issue.6, pp.932-977, 2007. ,
Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer, Eur J Cancer, vol.108, pp.111-119, 2019. ,